Prostate cancer survivors are the largest group of male cancer survivors (41%) and most are over age 65.1 Following curative-intent surgery or radiation, some data suggest interventions given shortly after early detection of biochemical recurrence (i.e., isolated prostate-specific antigen [PSA] elevation) may improve prostate cancer-specific survival.2 However, PSA monitoring may lead to complications from invasive diagnostics or treatment, and may be unnecessary in older men with a history of low-risk cancer or limited life expectancy due to the long lead time (5–8 years) between PSA biochemical recurrence and metastatic disease.2, 3 Therefore, we examined national VA and Medicare data of older men treated for localized prostate cancer with radiation or radical prostatectomy to determine if PSA monitoring is more frequent among older men with substantial life expectancy and/or history of high-risk cancer, who are most likely to benefit, and less frequent among older men with significant comorbidity and/or history of low-risk cancer who are most likely to experience harms without benefit.


We used the VA Central Cancer Registry to conduct a longitudinal cohort study of 13,397 men age 65 or older who were newly diagnosed with clinically localized prostate cancer between 1/1/03 and 12/31/08, received initial curative-intent radical prostatectomy or radiation, and survived without biochemical recurrence for at least 1 year after treatment. All men were followed for 4 years after their 1-year treatment anniversary date using national VA and Medicare data. We excluded men who did not have VA or Medicare as their primary insurance and those enrolled in Medicare HMO during the study period because they lacked claims to determine comorbidities or PSA monitoring.

Our main outcome was the number of PSA tests performed per person-year across all four survivorship years and for each survivorship year separately. For example, survivorship year 1 was defined as days 365–729 post-treatment to avoid including PSA tests performed during or immediately after treatment as most men would have completed treatment within a year.

We used Poisson regression models to estimate the number of PSA tests performed per person-year for baseline patient and tumor characteristics, with censoring at time of biochemical recurrence or death. Death was determined by the VA Vital Status file.


Baseline characteristics and associated PSA monitoring frequencies are presented in Table 1. No tumor or patient characteristic was associated with greater than 2.1 PSA tests per person-year or less than 1.8 PSA tests per person-year. Similarly, within each cancer recurrence risk group, men with limited life expectancy received slightly more PSA tests per person-year compared to men with favorable life expectancy (overall P < 0.001) (Fig. 1). Also, men with limited life expectancy treated for low-risk cancer, who are least likely to experience prostate cancer recurrence in their life time, received 1.9 PSA tests per person-year. This is only slightly lower than men with favorable life expectancy treated for high-risk cancer, who received 2.0 PSA tests per person-year (P < 0.001).

Table 1 Baseline Characteristics and Frequency of PSA Monitoring for Recurrence During Survivorship Years 1–4 (N = 13,397 Men Aged 65 Years or Older Treated for Localized Prostate Cancer with Curative-Intent*)
Figure 1
figure 1

Frequency of PSA monitoring during survivorship years 1–4, according to tumor characteristics predictive of recurrence risk and patient characteristics predictive of life expectancy . Tumor characteristics: Low-risk cancer = stage ≤ T2a, PSA level ≤ 10 ng/ml, and Gleason score ≤ 6; intermediate-risk cancer = stage T2b, or PSA level 10.1–20 ng/ml or Gleason score = 7; and high-risk cancer = stage T2c–T3b or PSA level > 20 ng/ml or Gleason score ≥ 8. 4 Patient characteristics: limited life expectancy = men aged 85 years and older with Charlson Comorbidity Index (CCI) ≥ 1 or those aged 65 years and older with CCI ≥ 4; favorable life expectancy = men aged 65–74 years with CCI = 0; and intermediate life expectancy = everyone else.

Also, predictors of PSA monitoring were generally consistent within each survivorship year. However, the number of PSA tests decreased from 2.3 PSA tests per person-year in survivorship year 1, to 2.0 in year 2, 1.8 in year 3, and 1.6 in year 4 (P < 0.001 for trend).


We found most men received approximately two PSA tests per year over survivorship years 1–4, which is consistent with national guidelines and two earlier studies.5, 6 However, prior studies did not include men treated with radiation or determine PSA monitoring according to life expectancy or tumor characteristics. We found a narrow range of PSA monitoring frequencies across patient and tumor characteristics, indicating little individualization of PSA monitoring. The strongest predictor of decreased PSA monitoring was time since treatment.

This is the largest national study to determine the use of PSA monitoring in older prostate cancer survivors following curative-intent surgery or radiation. Limitations include lack of PSA results in the 10% of tests performed in Medicare. Also, generalizability of our findings to non-veterans is uncertain. However, the VA is the largest US healthcare system. Our findings suggest a need for guidelines to encourage PSA monitoring as an informed decision that considers life expectancy, risk of recurrence and values/preferences of cancer survivors rather than a one-size-fits-all approach.